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Recently published articles have reported the controversial data regarding expression of 
aldehyde dehydrogenase isozyme 1A1 (ALDH1A1), a potential candidate marker for normal 
and cancer stem cells (CSCs), in thyroid tissues. These data prompted us to re-evaluate 
expression of ALDH1A1 in normal and cancerous thyroid tissues by two different means. The 
first method was immunohistochemistry with two different anti-ALDH1A1 antibodies from 
distinct companies. Following validating the integrity of these two antibodies by western 
blotting with ALDH-expressing and -non-expressing cancer cell lines and 
immunohistochemistry with breast and colon tissues, we here demonstrated significant and 
comparable expression of ALDH1A1 in both normal and cancerous thyroid tissues with both 
antibodies. Next, relative expression levels of ALDH isozymes were evaluated by reverse 
transcription-polymerase chain reaction (RT-PCR), revealing that ALDH1A1 was the most 
highly expressed isozyme followed by ALDH9A1 and relative expression patterns of isozymes 
were very similar in normal and cancerous tissues. All these data demonstrate that thyroid cells 
of normal and cancer origins do express ALDH1A1 and to a lesser extent 9A1. Further study 
will be necessary to study functional significance of ALDH1A1 in the function and behaviors of 
thyroid normal and cancer stem cells. 
 







   It has recently become apparent that a small subpopulation of cancer cells, called cancer 
stem cells (CSCs) or cancer initiating cells, are crucial not only for the initiation, but also for the 
propagation, recurrence and metastasis of cancers [1] . Enormous efforts have so far been made 
to identify CSC’s biological markers, of which aldehyde dehydrogenase (ALDH) appears to be 
highly promising [2]. Indeed Todaro et al. [3] have recently reported the usefulness of 
ALDH1A1 as a CSC marker for thyroid cancers. In their work, ALDH1A1-positive thyroid 
cancer cells directly isolated from cancer tissues were shown to be capable of forming spheres 
in vitro, a biological marker for CSCs, and tumors in vivo. Importantly, it has also been 
demonstrated by immunohistochemistry that normal thyroid cells rarely express ALDH1A1, but 
thyroid cancers express higher levels of ALDH1A1 as they dedifferentiate (3 + 1.2 % in 
follicular thyroid cancers, 7 + 1.8 % in papillary thyroid cancers (PTC) and 16 + 4 % in 
undifferentiated thyroid cancers).  In contrast, however, another report by Deng et al. [4] has 
shown the high levels of ALDH1A1 expression in virtually all the normal thyroid cells using the 
same antibody (BD Biosciences, clone #44/ALDH) and the same method. They thus proposed 
that ALDH1A1 should not be used as a CSC marker in tissues that normally express a high level 
of ALDH1A1 including thyroids.   
In the present study, we therefore re-evaluated expression of ALDH1A1 by 
immunohistochemistry, and, because there are 19 ALDH isozymes in humans [2,5], also 
examined relative expression levels of each ALDH isozymes by reverse 
transcription-polymerase chain reaction (RT-PCR), in normal and cancerous thyroid tissues.  
We here show that normal and cancerous thyroid tissues clearly express the significant and 
comparable levels of ALDH with ALDH1A1 isozyme being dominant (and to a lesser degree 









   Formalin-fixed and paraffin-embedded tissues from 18 pairs of normal thyroid and PTC 
tissues and three pairs of normal and cancerous tissues of colon and breast were obtained from 
the surgical pathology archives of Department of Tumor and Diagnostic Pathology, Nagasaki 
University, Japan. All experiments were performed after obtaining approval by the Ethical 
Committee of Nagasaki University Hospital. The tissues were cut into 4-µm-thick sections, 
deparaffinized and subjected to antigen retrieval by microwave treatment in citrate buffer. 
Following blockade of endogenous peroxidase with 0.3 % hydrogen peroxide in methanol for 
20 min, the tissue sections were incubated with the first antibodies of mouse anti-ALDH1A1 
antibody (#44/ALDH, BD Biosciences, San Jose, CA, USA; diluted at 1:1,500 to 6,000 or 
sc-374149, Santa Cruz (SC) Biotechnology Inc., Santa Cruz, CA, USA; diluted at 1:1,500 to 
10,000). The reaction products were visualized by the avidin-biotin-peroxidase technique using 
a Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA) and liquid DAB+ 
Substrate (K3468, Dako Corporation, Carpinteria, CA, USA). Finally, the sections were 
counterstained with hematoxylin and mounted. The staining was quantified by scoring the 
percentage of ALDH1A1-positive cells; score 4 indicates that >75% cells express ALDH1A1, 
score 3 51-75%, score 2 25-50% and score 1 <25%.   
 
Real-Time Quantitative RT-PCR 
 
Ten pairs of frozen PTC and adjacent normal tissue samples were used. Again, all 
experiments were performed after obtaining approval by the Ethical Committee of Nagasaki 
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University Hospital. Written informed consent was obtained from each individual. Total RNA 
was extracted using ISOGEN reagent (Nippon Gene, Tokyo, Japan). Complementary DNA was 
synthesized from 500 ng of total RNA with SuperScript III reverse transcriptase (Invitrogen, 
Carlsbad, CA, USA) in the presence of random hexamers according to the protocol 
recommended by the manufacturer. Quantitative PCR was then carried out in a Thermal Cycler 
Dice Real-time system (TaKaRa Bio, Tokyo, Japan) using SYBR Premix Ex Taq II (Takara).  
The sequences of primer pairs used were described in the Supporting information. The cycle 
threshold values, which were determined using second derivative, were used to calculate the 
normalized expression of the indicated mRNAs using Q-Gene software using β-actin for 





Total cell lysates were isolated from a human hepatoma cell line HepG2 and a human PTC 
cell line TPC-1. Fifty µg proteins were used for immunoblotting. The signal was developed with 
two anti-ALDH1A1 antibodies mentioned above and horse radish peroxidase ABC method 
(Vectastain ABC kit). To confirm equal loading, membranes prepared in parallel were probed 




ALDH activity was measured with an ALDEFLUOR assay kit (Aldagen/Cytomedix Inc. 
Gaithersburg, MD, USA) according to the manufacturer’s protocol; labeling was performed for 
30 min. Diethylaminobenzaldehyde (DEAB), an inhibitor of ALDH activity, was used as a 
negative control. The labeled cells were analyzed using a FACS Vantage SE with a ClonCyt 
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   Two anti-ALDH1A1 monoclonal antibodies were used in this study. One is an 
anti-ALDH1A1 monoclonal antibody from BD (#44/ALDH), used by Todaro et al. [3] and 
Deng et al. [4]. The antigen used to isolate this antibody was amino acids 7-128 of human 
ALDH1A1. The other is a monoclonal antibody from SC (sc-374149) whose epitope is mapped 
to amino acids 105-137.   
   To validate the integrity of these two antibodies, we first used two cancer cell lines HepG2 
and TPC. The former was positive, but the latter was negative, for ALDH expression as 
demonstrated by ALDOFLUOR assay and RT-PCR (Fig. 1A and B). As shown in Fig. 1C, the 
appropriate sizes of ALDH1A1 protein (~55 kDa) were visualized in HepG2, but not in TPC, 
cells with both antibodies. The next experiments, that is, immunohistochemical analysis of 
ALDH1A1 expression with these two antibodies in formalin-fixed, paraffin-embedded colon 
and breast tissues, were performed to determine the specificities and appropriate dilutions of 
each antibody. In normal parts of these tissues, putative localization sites of ALDH-positive 
stem/progenitor cells are known [4]. Among the different dilutions of antibodies (see Methods), 
BD antibody at a 1:1,500 dilution and SC antibody at a 1:10,000 dilution gave the best staining 
of normal stem cells in these tissues. The representative pictures are shown in Fig.1 D. 
Cancerous lesions of these tissues also expressed variable levels of ALDH1A1 as reported in the 
previous report [4] (Fig.1 D). No staining was confirmed by omitting addition of the first 
antibodies (data not shown). Altogether, these data clearly show that both antibodies react well 
with ALDH1A1 protein.   
   Eighteen pairs of formalin-fixed, paraffin-embedded normal and cancerous thyroid tissues 
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were then subjected to immunohistochemical analysis. The aforementioned dilutions of each 
antibody were used in these experiments. As shown in Fig. 2A and B, very similar results were 
obtained with two antibodies. Thus, over 75 % cells were positive for ALDH1A1 staining in 
approximately two thirds of normal tissues, and 50-75 % positivity in the rest of tissues. The 
similar staining pattern was also observed in cancerous tissues despite totally negative staining 
in a few samples. The staining scores were not significantly different between cancerous and 
normal tissues [3.8 + 0.1 (mean + SE) in cancers and 3.2 + 0.3 in normal tissues with BD 
antibody and 3.2 + 0.3 in cancers and 3.7 + 0.1 in normal tissues with SC antibody]. The 
pictures of representative staining were shown in Fig. 2A.  
   As mentioned earlier, 19 different isozymes have so far been identified in human ALDH 
[2,5]. Therefore, expression of all these isozymes was quantified by RT-PCR in 10 pairs of 
normal and cancerous thyroid tissues. Fig. 3 shows the average expression levels in 10 tissues 
(Fig. 3B) and also those in the representative three cases (Fig. 3A). Our data clearly 
demonstrated that ALDH1A1 was the most highly expressed isozyme in most of normal and 
cancerous tissues, followed by 9A1, although expression levels of each isozyme were variable 
in individual tissues. However, it should be noted that this kind of comparison may not be 
accurate because of different primer efficiencies in distinct primer sets. Also importantly, 
relative expression levels of each isozyme between normal and cancer tissues (Fig. 3B) were not 
significantly different.  
It may be worth noting that our preliminary microarray data obtained with a normal thyroid 
tissue (Mitsutake et al. unpublished) and the data from Geo DataSets with seven thyroid normal 
and cancer sets (GDS1732; http://www.ncbi.nlm.nih.gov/sites/GDSbrowser?acc=GDS1732) 
both demonstrated that the transcripts of eight isozymes are clearly expressed (ALDH1A1, 1B1, 







Recent contradictory data on ALDH1A1 expression in thyroid tissues [3,4] prompted us to 
re-evaluate these data by immunohistochemistry and also by RT-PCR. Two different 
anti-ALDH1A1 antibodies we used in this study were from distinct companies (BD and SC) and 
both recognized approximately 55 kD protein in immunoblotting, a size compatible to that of 
ALDH1A1, in the cells dominantly expressing 1A1 isozyme of ALDH and also detected normal 
and cancer stem cells in colon and breast tissues, validating the integrity of these antibodies, 
although the possibility of cross-reactivity of these antibodies with other ALDH isozymes 
cannot completely be excluded due to a high degree of amino acid sequence similarity [6].  
Indeed one of these antibodies was used in the previously published controversial studies [3,4].  
Our data obtained with these antibodies demonstrate significant and comparable levels of 
ALDH1A1 expression in normal and cancerous thyroid tissues. Furthermore, we also show 
clear expression of ALDH mRNA by RT-PCR in thyroid tissues with predominantly expressed 
ALDH isozyme being ALDH1A1 followed by ALDH9A1. We thus interpret all these data as 
indicating that thyroid cells of normal and cancer origins do express ALDH1A1. These data 
support those by Deng et al. [4], but sharply contradict those by Todaro et al [3].  
The similar discrepant data can also be reported in pancreas. Thus almost all normal and 
cancerous pancreatic cells express ALDH1A1 in one study [4] while the positivity is much 
lower in other studies with primary pancreatic tumors and xenografts [7].   
   As mentioned in the Introduction, ALDH is increasingly recognized as an important 
biological marker for CSCs. As with the data by Todaro et al. [3], we have also recently found 
that CSCs can be enriched for ALDH activity, determined by an ALDEFLUOR assay, in some, 
but not all, thyroid cancer cell lines [8]. Thus, we do not here intend to negate the importance of 
ALDH for thyroid CSC study and instead we think that ALDH may still be a useful marker to 
enrich thyroid CSCs.   
   Expression levels of ALDH isozymes vary in different cancerous tissues. Prostate CSCs 
express mainly ALDH7A1 and to a lesser degree 4A1 and 9A1 [9]; breast cancer CSCs 
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ALDH1A3 (and to a lesser degree 2, 4A1, 5A1, 6A1 and 7A1) [10]; and primary melanoma 
cells 1A1 and 1A3 and melanoma cell lines 1A3 [11].   
It is reported that ALDH is not just a marker for isolating or enriching CSCs but can 
modulate CSC properties [9,12-15], although the data are controversial. On the one hand, some 
articles reported the crucial role for ALDH in maintaining CSC characteristics. For example, 
ALDH1A1 silencing by siRNA sensitizes ovarian cancer cells to chemotherapy and reduces 
their tumorigenesis [14]; siRNA-mediated silencing of ALDH1A1 and 3A1 suppresses cell 
proliferation and motility in cancer cell lines [15]; and knockdown of ALDH7A1 by shRNA 
inhibits the clonogenic, migratory and metastatic activities in prostate cancer cells [9]. On the 
other hand, however, other reports demonstrated inhibition of CSC function by ALDH. Thus, 
inhibition of ALDH activity by DEAB and addition of all-trans retinoic acid (ATRA), a product 
by ALDH, augments and suppresses, respectively, sphere formation in cancer cell lines [13]. In 
thyroid cancers, anti-tumor effect of ATRA is also reported [16]. It thus may be of interest to 
clarify how ALDH activity modulates the characteristics of thyroid cancer cells and particularly 
thyroid CSCs.   
   In conclusion, we here show the significant expression of ALDH1A1 (and to a lesser extent 
9A1) in normal and cancerous thyroid tissues. Further study will definitely be necessary to 
study functional significance of the predominantly expressed ALDH1A1 in the behaviors of 







Figure 1. Expression of ALDH in ALDOFLUOR assay and RT-PCR, and of ALDH1A1 in 
western blotting and immunohistochemistry. (A) ALDEFLUOR assay with/without DEAB 
treatment, (B) RT-PCR analysis of mRNA for 19 ALDH isozyme expression, in two cancer cell 
lines and (C) immunoblotting of the total cell lysates extracted from two cancer cell lines with 
two anti-ALDH1A1 antibodies and anti-β-actin antibody were performed as described in the 
Materials and Methods. (D) Immunohistochemistry of ALDH1A1 expression with normal and 
cancerous tissues of colon and breast with two antibodies. The representative staining with 
1:1,500 diluted BD antibody and 1:10,000 diluted SC antibody was shown.  In (B), the arrows 
indicate β-actin or ALDH1A1 proteins, and * non-specific reaction.    
 
Figure 2. Expression of ALDH1A1 proteins in normal and cancerous thyroid tissues in 
immunohistochemical analysis. (A) The representative pictures of ALDH1A1 staining in normal 
and cancerous thyroid tissues with two different anti-ALDH1A1 antibodies are shown. 
Antibody dilutions were 1:1,500 for BD antibody and 1:10,000 for SC antibody. (B) 
ALDH1A1 expression in 18 pairs of normal and cancerous thyroid tissues estimated by 
immunostaining with two antibodies were summarized. The data are categorized into four 
groups according to percentage of ALDH1A1-positive cells: >75, 75 to 51, 50 to 25 and <25 %.   
 
Figure 3. Expression of mRNAs for 19 ALDH isozymes analyzed by RT-PCR. Total RNAs 
extracted from pairs of normal and cancerous thyroid tissues were subjected to RT-PCR as 
described in the Materials and Methods. (A) The representative data in three pairs are shown as 
means + ranges (n=2). (B) The averages of the data obtained with 10 pairs are summarized and 
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Table 1. The sequences of primers used to quantify mRNAs for ALDH 
isozymes.  
                                                                              
Primers used  Forward   Reverse 
                                                                              
1A1  TGTTAGCTGATGCCGACTTG TTCTTAGCCCGCTCAACACT 
1A2  CACAGTGTTTTCCAACGTCACT GGGCCTTGTTGATGTCATTAGT 
1A3  TCTCGACAAAGCCCTGAAGT TATTCGGCCAAAGCGTATTC 
1B1  AACCAGAACCCAAGCGTGAT TTGTTGATGAACAGCTGGTTGTA 
1L1  ATCTTTGCTGACTGTGACCT GCACCTCTTCTACCACTCTC 
1L2  GCCTGGTCTCGTTACCAAAA GCCACTTTCACCTCTTCAGC 
2  GGGTCAACTGCTATGATGTGTTT TTTCCATCAATGGCTGAGGGAGG 
3A1  GCAGACCTGCACAAGAATGA TGTAGAGCTCGTCCTGCTGA 
3A2  CCCCTTCGTTCTCACCATTC CTGAGGGAGAAGCTTTGCCA 
3B1  GGGCTTCTGTGGGAACGAC AGAACTTGCCATGGTACCGG 
3B2  ACAGAGGAAGGTCCTGGCTGA CATGACAATCTTGCCCACAC 
4A1  GTACGGTGGCCAGAAGTGTT TCTTGATACGGGCAAAGGAC 
5A1  ACCAATTCTTGGTGCAAAGG GTTGGTGTCGTTTTCCACCT 
6A1  GGCTCTTTCAACAGCAGTCC ATGGAAGCTCCCTCCTTTGT 
7A1  CAACGAGCCAATAGCAAGAG GCATCGCCAATCTGTCTTAC 
8A1  GCAGAGTGCCAAATAGTGGA AACTCCTCCAGGGACTGCT 
9A1  CACTCATCAACCGACCACAC GGACATAACAGGCCCAAAGA 
16A1  AGGATCCCATCACAGGAGAG ACTCCAGCCCTTAAATGCC 
18A1  CTGAGTATGGGGACCTGGAA GCGGTAACCATCAGAAAAGC 
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